2014
DOI: 10.1038/nutd.2014.42
|View full text |Cite
|
Sign up to set email alerts
|

The effect of bitter melon (Mormordica charantia) in patients with diabetes mellitus: a systematic review and meta-analysis

Abstract: Background:Mormordica charantia (bitter melon) has been investigated for lowering plasma glucose in patients with diabetes mellitus (DM). Previous data has offered inconclusive and inconsistent results about the benefits of bitter melon in patients with DM. Our current project aims to determine whether bitter melon has a favorable effect in lowering plasma glucose in patients with DM.Methods:We searched PubMed, EMBASE and the Cochrane Library from inception to July 2013 without any language restrictions for ra… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

1
20
0
1

Year Published

2017
2017
2022
2022

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 24 publications
(25 citation statements)
references
References 16 publications
1
20
0
1
Order By: Relevance
“…Later, several in vivo studies showed significant glucose lowering potential of whole fruits, fruit pulp, and seeds [14][15][16][17][18]. Based on these significant results of in vivo preclinical studies, a handful of clinical trials were conducted [10]; however, the majority of these trials failed to establish benefits of M. charantia L. in a systematic review conducted in 2014 [19]. Four years later, a meta-analysis of five trials confirmed significant glucose lowering ability of M. charantia L. with only very low certainty of evidence [10].…”
Section: Introductionmentioning
confidence: 99%
“…Later, several in vivo studies showed significant glucose lowering potential of whole fruits, fruit pulp, and seeds [14][15][16][17][18]. Based on these significant results of in vivo preclinical studies, a handful of clinical trials were conducted [10]; however, the majority of these trials failed to establish benefits of M. charantia L. in a systematic review conducted in 2014 [19]. Four years later, a meta-analysis of five trials confirmed significant glucose lowering ability of M. charantia L. with only very low certainty of evidence [10].…”
Section: Introductionmentioning
confidence: 99%
“…Momordica charantia Linnaeus (Family Cucurbitaceae) is the most studied herb for its anti-hyperglycemic effect in vivo and in clinical studies [ 16 , 17 ]. It is a tropical and subtropical vine, widely common in Brazil, Asia, and some parts of east Africa including Tanzania [ 18 ], and it has been commonly used as nutritional food and medicine for centuries.…”
Section: Introductionmentioning
confidence: 99%
“…The diversity of actions [ 22 , 23 ], has drawn significant attention from researchers in the field of drug discovery and resulting surge in clinical studies investigated its anti-hyperglycemic effects in T2DM. However, such studies have produced inconsistent findings in relation to clinical efficacy [ 17 ], and no systematic documentation of adverse effects has been undertaken [ 16 ]. Hence, the need for this systematic review and meta-analysis is to systematically review and synthesize evidences on the safety and efficacy of M. charantia as an alternative to conventional OHAs for the glycemic control in patients with type 2 diabetes mellitus.…”
Section: Introductionmentioning
confidence: 99%
“…Momordica charantia , also known as bitter melon (BM), has been purported to have an antihyperglycemic effect, which may serve as a treatment option for managing diabetes mellitus. 1 , 2 , 3 , 4 Further, the ingestion of BM has been shown to elicit an acute hypoglycemic effect 5 , 6 , 7 , 8 and improve the postprandial glycemic response during oral glucose tolerance testing among diabetics. 6 , 9 , 10 Conversely, others have reported no significant reduction in postprandial blood glucose concentrations during glucose tolerance testing among non-diabetics, 11 , 12 highlighting the notion that one's ability to maintain blood glucose homeostasis may determine the efficacy of BM.…”
Section: Introductionmentioning
confidence: 99%